Value-engineered translation for regenerative medicine: Meeting the needs of health systems

Authors

Tania M. Bubela, University of Alberta, CanadaFollow
Christopher McCabe, University of Alberta, Canada

Document Type

Article

Department

Office of the Provost

Abstract

Despite high expectations of economic returns, large investments in regenerative medicine technology have yet to materialize, partly due to a lack of proven business and investment models, regulatory hurdles, and a greater focus on cost-effectiveness for reimbursement decisions by payors. Adoption of new economic modeling methods will better link investment decisions to value-based criteria of health systems.

Comments

This work was published before Tania joined Aga Khan University.

Publication (Name of Journal)

Stem Cells and Development

DOI

10.1089/scd.2013.0398

Recommended Citation

Bubela, T. M., McCabe, C. (2013). Value-engineered translation for regenerative medicine: Meeting the needs of health systems. Stem Cells and Development, 22(Supp. 1), 89-93.
Available at: https://ecommons.aku.edu/provost_office/776